Sugar-free approach to treating Kaposi sarcoma

October 1, 2012

A sugar-loving protein drives the growth of Kaposi sarcoma (KS) tumors, according to a study published on October 1st in The Journal of Experimental Medicine. Interfering with these sugary interactions inhibited growth of Kaposi sarcomas in mice, hinting at the potential for new treatment strategies in humans.

KS is a cancer that is associated with infection with a called HHV-8 and is prevalent in HIV patients. Effective antiretroviral drugs have decreased the incidence of KS, but the cancer eventually progresses in many patients and treatment options are limited.

A carbohydrate-binding protein called galectin-1 is released by a variety of tumors and promotes their growth and metastasis. A group of researchers at the University of Buenos Aires in Argentina now finds that blocking galectin-1 in mice bearing established Kaposi sarcomas slowed tumor growth in part by suppressing the formation of blood vessels that feed the tumor.

If the same holds true in humans, drugs targeting galectin-1 could provide new treatment options for patients with KS. These drugs might also hold promise for other diseases characterized by aberrant , including macular degeneration and cardiovascular diseases.

Explore further: DNA damage response confers a barrier for viral tumorigenesis

More information: Croci, D.O., et al. 2012. J. Exp. Med. doi:10.1084/jem.20111665

Related Stories

DNA damage response confers a barrier for viral tumorigenesis

September 28, 2007

Kaposi’s sarcoma herpesvirus (KSHV) is a human tumor virus and an etiological agent for Kaposi’s sarcoma (KS). KSHV infection is endemic in sub-Saharan Africa where KS is nowadays the most common malignancy, due to widespread ...

Scientists reveal new targets for anti-angiogenesis drugs

August 16, 2010

A new study describes how a carbohydrate-binding protein, galectin-3, promotes angiogenesis, the growth of new blood vessels. Targeting the protein, scientists identified two approaches that significantly reduced angiogenesis ...

A culprit behind brain tumor resistance to therapy

March 5, 2012

Persistent protein expression may explain why tumors return after therapy in glioblastoma patients, according to a study published on March 5th in the Journal of Experimental Medicine.

Bevacizumab active in HIV-linked Kaposi's sarcoma

March 20, 2012

(HealthDay) -- For patients with HIV-associated Kaposi's sarcoma (HIV-KS), bevacizumab is tolerated and induces a response in some patients, according to a study published online March 19 in the Journal of Clinical Oncology.

Recommended for you

Molecularly shutting down cancer cachexia

August 30, 2016

Healthy fat tissue is essential for extended survival in the event of tumor-induced wasting syndrome (cachexia). In Nature Medicine, researchers at Helmholtz Zentrum München show that selective manipulation of an enzyme ...

Radiologists detect breast cancer in 'blink of an eye'

August 29, 2016

A new study by investigators at Brigham and Women's Hospital in collaboration with researchers at the University of York and Leeds in the UK and MD Andersen Cancer Center in Texas puts to the test anecdotes about experienced ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.